Drugs and Implants in Orthopedic Surgery and Traumatology

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 786

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Musculoskeletal Tissue Regeneration, Orthopaedic Hospital König-Ludwig-Haus, University of Würzburg, Wurzburg, Germany
2. Department of Orthopaedic Surgery, Orthopaedic Hospital König-Ludwig-Haus, University of Würzburg, Wurzburg, Germany
Interests: orthopedic and trauma implants; muscle; osteoarthritis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Orthopedic and trauma surgery increasingly leverages drug–device combinations to prevent and treat infection, modulate inflammation and pain, and accelerate bone regeneration and cartilage repair. From antibiotic‑loaded bone cement and antimicrobial implant coatings to bioresorbable carriers and 3D‑printed scaffolds with controlled release, the therapeutic interface between pharmacology and implant technology is rapidly evolving. This Special Issue of Pharmaceuticals invites preclinical and clinical studies that clarify local pharmacokinetics/pharmacodynamics, release kinetics, and tissue distribution in peri‑implant environments; strategies against biofilm and chronic osteomyelitis (including local versus systemic delivery); effects of surface modifications on osseointegration and immune response; and the safety, effectiveness, and cost‑effectiveness of drug–implant therapies across hip, knee, shoulder, foot and ankle, spine, and trauma applications. We particularly welcome randomized trials, registry and real‑world evidence, translational and mechanistic work, high‑quality reviews and meta‑analyses, and technical notes on design, modeling, and quality control. By bringing together orthopedics, materials science, microbiology, and pharmaceutical sciences, this issue aims to define best practices and guide the next generation of safe and effective drug–implant strategies in musculoskeletal care.

Dr. Ioannis Stratos
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug–device combinations
  • orthopedic and trauma implants
  • local drug delivery
  • periprosthetic joint infection (PJI)
  • biofilm prevention
  • antimicrobial coatings
  • antibiotic‑loaded bone cement
  • release kinetics (PK/PD)
  • bioresorbable implants
  • fracture healing and bone regeneration

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 5409 KB  
Article
Tailored Phytochitosomes as Targeted Nanotherapy for Alveolar Bone Regeneration in Diabetic Obese Rats
by Yosra S. R. Elnaggar, Mariam Zewail, Eman M. Salem, Wafaa Y. Alghonemy, Nevien M. Ahmed, Rania A. Hanafy, Waiel Daghistan, Ali M. Alaseem, Dina Khodeer, Elsayed G. Zaki, Ahmad N. Almougy and Mona A. Moustafa
Pharmaceuticals 2026, 19(3), 506; https://doi.org/10.3390/ph19030506 - 19 Mar 2026
Viewed by 467
Abstract
Background/Objectives: Individuals with diabetes often experience difficulties in the healing of their alveolar sockets. Furthermore, obesity is strongly associated with the development and progression of type 2 diabetes through complex metabolic and inflammatory mechanisms. The current study provides new insights into the [...] Read more.
Background/Objectives: Individuals with diabetes often experience difficulties in the healing of their alveolar sockets. Furthermore, obesity is strongly associated with the development and progression of type 2 diabetes through complex metabolic and inflammatory mechanisms. The current study provides new insights into the use of Luteolin (LU) and/or chitosan vesicles (CHV) to accelerate bone regeneration, highlighting a biologically and clinically relevant approach that leverages implants as a clinical solution. Methods: Sixty rats were randomly categorized into five groups: Group I (negative control); Group II (positive control), diabetic and obese rats; Group III (LU-treated), diabetic and obese rats with an extraction socket loaded with LU; Group IV (CHV-treated), diabetic and obese rats with an extraction socket loaded with CHV; and Group V (LU-CHV), diabetic and obese rats with an extraction socket loaded with LU-CHV. After 2 and 6 weeks, rats’ mandibles underwent histological, histomorphometric, biochemical, and statistical analyses. Results: The results demonstrated significant differences among the experimental groups. The LU-CHV formulation showed superior therapeutic performance compared with free luteolin and the untreated control group. In vitro release studies revealed sustained, controlled release from LU-CHV, whereas free luteolin exhibited rapid drug release. Additionally, LU-CHV significantly enhanced biological activity, as evidenced by improved anti-inflammatory and/or therapeutic markers compared to the other groups. These findings indicate that encapsulation within chitosan vesicles improved drug stability, bioavailability, and overall therapeutic efficiency. Conclusions: LU-CHV demonstrated superior efficacy compared to free luteolin, highlighting the advantage of chitosan-based vesicular delivery systems. LU-CHV not only enhanced controlled drug release and therapeutic outcomes but also presents a promising platform that could significantly advance targeted drug delivery strategies in inflammatory and metabolic disorders. The findings suggest that LU-CHV represents a transformative approach in improving treatment effectiveness and patient outcomes. Full article
(This article belongs to the Special Issue Drugs and Implants in Orthopedic Surgery and Traumatology)
Show Figures

Graphical abstract

Back to TopTop